Loading...
TARA logo

Protara Therapeutics, Inc.NasdaqGM:TARA Aktierapport

Marknadsvärde US$276.5m
Aktiekurs
US$4.92
US$26.57
81.5% undervärderad intrinsisk rabatt
1Y57.2%
7D-3.5%
1D
Portföljens värde
​
Utsikt

Protara Therapeutics, Inc.

NasdaqGM:TARA Aktierapport

Börsvärde: US$276.5m

Protara Therapeutics (TARA) Aktievy

Protara Therapeutics, Inc. är ett biofarmaceutiskt företag i klinisk fas som utvecklar innovativa terapier för behandling av cancer och sällsynta sjukdomar. Mer information

TARA fundamental analys
Snöflinga Score
Värdering5/6
Framtida tillväxt2/6
Tidigare resultat0/6
Finansiell hälsa6/6
Utdelningar0/6

Belöningar

Handlar till 97.6% under vår uppskattning av dess verkliga värde

Intäkterna förväntas växa med 65.99% per år

Analytiker är överens om att aktiekursen kommer att stiga med 440.1%

Riskanalys

Ger mindre än 1 miljon USD i intäkter ( $0 )

Aktieägarna har varit kraftigt utspädda under det senaste året

För närvarande olönsamt och förväntas inte bli lönsamt under de kommande 3 åren


TARA Community Fair Values

Create Narrative

See what 15 others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

Protara Therapeutics, Inc. Konkurrenter

Prishistorik och prestanda

Sammanfattning av aktiekursernas upp- och nedgångar samt förändringar för Protara Therapeutics
Historiska aktiekurser
Aktuell aktiekursUS$4.92
52 veckors högstaUS$7.82
52 veckors lägstaUS$2.77
Beta1.53
1 månads förändring-4.09%
3 månaders förändring-33.78%
1 års förändring57.19%
3 års förändring66.78%
5 års förändring-48.10%
Förändring sedan börsintroduktionen-83.60%

Senaste nyheter och uppdateringar

Recent updates

Seeking Alpha • Dec 04

Protara Therapeutics: End Of 2025 Proving Eventful Indeed

Summary Protara Therapeutics maintains strong momentum with TARA-002, showing durable, high complete response rates in NMIBC and promising efficacy in lymphatic malformations. TARA-002’s 6-month complete response rate of 69% in BCG-naive NMIBC patients and 100% clinical success in lymphatic malformations reinforce its competitive positioning. With over two years of cash runway, TARA is well-capitalized to reach pivotal regulatory and clinical milestones without near-term dilution risk. I maintain a 'Buy' rating on TARA, though with tempered conviction, as positive data and market opportunity are balanced by evolving competition and volatility. Read the full article on Seeking Alpha
Analysartikel • Jul 10

We Think Protara Therapeutics (NASDAQ:TARA) Can Afford To Drive Business Growth

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Seeking Alpha • Mar 28

Protara Therapeutics: Speculative Buy On Promising TARA-002 Trial Results

Summary TARA’s leading candidate is TARA-002, which so far looks like a promising immune-stimulating therapy derived from OK-432 (Picibanil). Their recent Phase 2 ADVANCED-2 trial also showed favorable results in NMIBC, with a notable 72% complete response rate at six months. TARA’s pipeline also has IV Choline, which could target unmet needs in patients requiring parenteral nutrition, and it has no other FDA-approved alternatives. I also believe their cash reserves and recent raise secure their runway, at least until 2027. So, even though TARA remains a relatively speculative microcap, I believe it trades at a compelling valuation in light of its potential. So I rate it a “Buy” at these levels. Read the full article on Seeking Alpha
Analysartikel • Mar 07

We're Hopeful That Protara Therapeutics (NASDAQ:TARA) Will Use Its Cash Wisely

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Dec 10

Protara: Six-Month NMIBC Treatment Data Bodes Well For Mid-2025 Catalyst

Summary Initial data from the phase 2 ADVANCED-2 study, using TARA-002 for the treatment of patients with non-muscle invasive bladder cancer, is expected by mid-2025. The global bladder cancer market size is expected to reach $5.4 billion by 2034. Initial results from the phase 2 STARBORN-1 study, using TARA-002 for the treatment of pediatric patients with macroystic and mixed cystic LMs, are expected in the 1st half of 2025. Dosing of first patients in phase 3 THRIVE-3 study, using IV choline chloride for parenteral support patients, are expected in Q1 of 2025. The company had $81.5 million in cash as of September 30th of 2024; Despite the cash runway, management chose to raise approximately $100 million through an underwritten public offering. Read the full article on Seeking Alpha
Analysartikel • Nov 22

Here's Why We're Watching Protara Therapeutics' (NASDAQ:TARA) Cash Burn Situation

We can readily understand why investors are attracted to unprofitable companies. For example, Protara Therapeutics...
Analysartikel • Aug 08

Is Protara Therapeutics (NASDAQ:TARA) In A Good Position To Invest In Growth?

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Seeking Alpha • Feb 22

Protara: A Bombed Out Biotech With A Very Positive Skew

Summary Protara Therapeutics is developing therapies for cancer and rare diseases, with a focus on non-muscle invasive bladder cancer and lymphangiomas. The company's main candidate, TARA-002, is being tested in phase 2 trials for NMIBC and lymphangiomas, with preliminary results expected in H1 2024. Protara is trading below its cash value, presenting a potential undervaluation opportunity if its phase 2 trials are successful. Read the full article on Seeking Alpha
Analysartikel • Dec 16

Here's Why We're Watching Protara Therapeutics' (NASDAQ:TARA) Cash Burn Situation

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Analysartikel • Apr 22

We Think Protara Therapeutics (NASDAQ:TARA) Can Afford To Drive Business Growth

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Seeking Alpha • Oct 13

The Prognosis For Protara Therapeutics

Summary We put small biopharma concern Protara Therapeutics in the spotlight today for the first time in more than 18 months. The stock has seen some small insider buying throughout 2022 and the shares sell for less than 50% of the company's net cash on the balance sheet. An investment analysis follows in the paragraphs below. Men are never convinced of your reasons, of your sincerity, of the seriousness of your sufferings, except by your death. So long as you are alive, your case is doubtful; you have a right only to their skepticism.”― Albert Camus We took our first look at Protara Therapeutics (TARA) back in the first quarter of 2021. No one on Seeking Alpha has provided coverage on the company since. Given I get an occasional question around Protara, today we are going to circle back on this small biopharma concern. An updated analysis follows below. Seeking Alpha Company Overview: Protara Therapeutics was formed when Proteon Therapeutics merged with privately held ArTara Therapeutics in late 2019. The company is based in New York City and is focused on developing transformative therapies for the treatment of cancer and rare diseases with significant unmet needs. The stock currently trades around $3.50 a share and has an approximate market capitalization of $40 million. March Company Presentation The company's pipeline consists mainly of one key compound in development. Protara's lead pipeline asset is TARA-002. It is in development for the treatment of lymphatic malformations [LMs] and non-muscle invasive bladder cancer (NMIBC). It has a Rare Pediatric Disease designation for LMs. March Company Presentation The company received preliminary guidance regarding a development path for TARA-002 in lymphatic malformations in the first quarter of this year from the FDA. March Company Presentation Management's plan is to initiate a Phase 2 clinical trial in this indication, subject to alignment with FDA on the clinical trial protocol. LMs are rare, congenital malformations of lymphatic vessels resulting in the failure of these structures to connect or drain into the venous system. Most LMs are present in the head and neck region and are diagnosed in early childhood during the period of active lymphatic growth. March Company Presentation The first patient was dosed in Phase 1 trial evaluating TARA-002 to treat NMIBC in the first quarter of 2022. NMIBC represents 80% of all bladder cancer, which is the sixth most frequent time of cancer in the world. Approximately 65,000 patients are diagnosed with NMIBC in the United States each year. March Company Presentation When TARA-002 is administered, it is hypothesized that innate and adaptive immune cells within the cyst or tumor are activated and produce a strong immune cascade. TARA-002 was developed from the same master cell bank of genetically distinct group A Streptococcus pyogenes as OK-432, a broad immunopotentiator marketed as Picibanil® in Japan and Taiwan. March Company Presentation The company is also doing a prospective study to enhance its understanding of the incidence of Intestinal Failure Associated Liver Disease or IFALD in patients dependent on parenteral nutrition that remains ongoing. The company did get a key patent for this potential IV Choline Chloride program in April of this year. This candidate is an investigational, intravenous (IV) phospholipid substrate replacement therapy. There doesn't seem to be much movement in this program since we last looked at Protara in February of 2021. March Company Presentation Analyst Commentary & Balance Sheet: The company gets sparse commentary on Wall Street. In 2022, Oppenheimer ($32 price target), H.C. Wainwright ($23 price target) and Ladenberg Thalmann ($32 price target) have maintained Buy ratings on the stock. These are the only analyst firms I can find that have chimed in around Protara so far this year. Approximately two percent of the outstanding float in the shares are currently held short. At the end of the second quarter, the company had nearly $100 million of cash and marketable securities on its balance sheet against no long term debt. Management has guided that this cash balance is sufficient to fund all planned activities until mid-2024. The company had a net loss of $8.5 million in 2Q2022.
Analysartikel • Sep 12

Here's Why We're Not Too Worried About Protara Therapeutics' (NASDAQ:TARA) Cash Burn Situation

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Analysartikel • Mar 21

Will Protara Therapeutics (NASDAQ:TARA) Spend Its Cash Wisely?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Analysartikel • Dec 06

Is Protara Therapeutics (NASDAQ:TARA) In A Good Position To Deliver On Growth Plans?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Aktieägarnas avkastning

TARAUS BiotechsUS Marknad
7D-3.5%1.2%1.1%
1Y57.2%34.6%28.7%

Avkastning vs industri: TARA översteg US Biotechs branschen som gav 34.6 % under det senaste året.

Avkastning vs Marknaden: TARA översteg US marknaden som gav 28.7 % under det senaste året.

Prisvolatilitet

Is TARA's price volatile compared to industry and market?
TARA volatility
TARA Average Weekly Movement8.9%
Biotechs Industry Average Movement10.8%
Market Average Movement7.2%
10% most volatile stocks in US Market16.5%
10% least volatile stocks in US Market3.1%

Stabil aktiekurs: TARA har inte haft någon betydande prisvolatilitet under de senaste 3 månaderna jämfört med marknaden för US.

Volatilitet över tid: TARA s veckovolatilitet ( 9% ) har varit stabil under det senaste året.

Om företaget

GrundadAnställdaVD OCH KONCERNCHEFWebbplats
n/a46Jesse Sheffermanwww.protaratx.com

Protara Therapeutics, Inc. är ett biofarmaceutiskt företag i klinisk fas som arbetar med att utveckla transformativa terapier för behandling av cancer och sällsynta sjukdomar. Bolagets ledande program är TARA-002, en prövningsbaserad cellterapi, som befinner sig i klinisk fas II-studie för behandling av icke-muskelinvasiv blåscancer och lymfatiska missbildningar. Bolaget utvecklar också intravenös kolinklorid, en läkemedelsterapi som ersätter fosfolipidsubstrat för patienter som får parenteral nutrition och vätska.

Protara Therapeutics, Inc. Sammanfattning av grunderna

Hur förhåller sig Protara Therapeutics:s resultat och omsättning till dess börsvärde?
TARA grundläggande statistik
BörsvärdeUS$276.52m
Vinst(TTM)-US$63.31m
Intäkter(TTM)n/a
0.0x
P/S-förhållande
-4.4x
P/E-förhållande

Är TARA övervärderat?

Se Verkligt värde och värderingsanalys

Resultat & intäkter

Viktig lönsamhetsstatistik från den senaste resultatrapporten (TTM)
TARA resultaträkning (TTM)
IntäkterUS$0
Kostnad för intäkterUS$0
BruttovinstUS$0
Övriga kostnaderUS$63.31m
Intäkter-US$63.31m

Senast redovisade vinst

Mar 31, 2026

Nästa vinstdatum

n/a

Vinst per aktie (EPS)-1.13
Bruttomarginal0.00%
Nettovinstmarginal0.00%
Skuld/egenkapitalförhållande0%

Hur har TARA utvecklats på lång sikt?

Se historisk utveckling och jämförelse

Företagsanalys och finansiella data Status

UppgifterSenast uppdaterad (UTC-tid)
Analys av företag2026/05/24 07:35
Aktiekurs vid dagens slut2026/05/22 00:00
Intäkter2026/03/31
Årlig intjäning2025/12/31

Datakällor

Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.

PaketUppgifterTidsramExempel US-källa
Företagets finansiella ställning10 år
  • Resultaträkning
  • Kassaflödesanalys
  • Balansräkning
Analytikernas konsensusuppskattningar+3 år
  • Prognos för finansiella poster
  • Analytikernas prismål
Marknadspriser30 år
  • Aktiekurser
  • Utdelningar, splittar och åtgärder
Ägarskap10 år
  • Största aktieägare
  • Insiderhandel
Förvaltning10 år
  • Ledningsgrupp
  • Styrelse och verkställande direktörer
Viktiga utvecklingstendenser10 år
  • Företagsmeddelanden

* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.

Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.

Analysmodell och snöflinga

Detaljer om analysmodellen som användes för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och tutorials på Youtube.

Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.

Industri- och sektormått

Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.

Källor för analytiker

Protara Therapeutics, Inc. bevakas av 10 analytiker. 7 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.

AnalytikerInstitution
Li Wang WatsekCantor Fitzgerald & Co.
Andrew FeinH.C. Wainwright & Co.
Andres MaldonadoH.C. Wainwright & Co.